David J Chung

Memorial Sloan Kettering Cancer Center

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

3 more share only the name and are not shown

Trial papers

PubMed author-name match

Trials

Studies that name David J Chung as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:49 UTC. Open this list on ClinicalTrials.gov

Ph1/Ph2
NCT01827137 · WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group · completed · Multiple Myeloma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:49 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
JAMA Oncol · 2021
105 citations
RCR 5.2
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Lancet Haematol · 2021
89 citations
RCR 4.8
The effect of early isolated lumbar extension exercise program for patients with herniated disc undergoing lumbar discectomy.
Neurosurgery · 2005
73 citations
RCR 3.3
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Blood · 2014
72 citations
RCR 2.0
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
Clin Cancer Res · 2011
61 citations
RCR 1.4
Comparison of the efficacy of Burch colposuspension, pubovaginal sling, and tension-free vaginal tape for stress urinary incontinence.
Int J Gynaecol Obstet · 2005
51 citations
RCR 2.0
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
Blood · 2012
47 citations
RCR 1.0
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biol Blood Marrow Transplant · 2018
39 citations
RCR 1.4
Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Blood Adv · 2022
37 citations
RCR 2.4
Assessment of factors associated with the quality of life in Korean type 2 diabetic patients.
Intern Med · 2013
30 citations
RCR 1.5